MA30345B1 - Formulation d'anticorps monoclonal humain anti-igf-1r - Google Patents

Formulation d'anticorps monoclonal humain anti-igf-1r

Info

Publication number
MA30345B1
MA30345B1 MA31308A MA31308A MA30345B1 MA 30345 B1 MA30345 B1 MA 30345B1 MA 31308 A MA31308 A MA 31308A MA 31308 A MA31308 A MA 31308A MA 30345 B1 MA30345 B1 MA 30345B1
Authority
MA
Morocco
Prior art keywords
igf
monoclonal antibody
human monoclonal
antibody formulation
formulation
Prior art date
Application number
MA31308A
Other languages
English (en)
Inventor
Adelbert Grossmann
Hanns-Christian Mahler
Astrid Pappenberger
Oliver Boris Stauch
Jan Olaf Stracke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30345B1 publication Critical patent/MA30345B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation d'anticorps monoclonal humain anti-IGF-1R, un procédé pour la préparation et les utilisations de celle-ci.
MA31308A 2006-03-28 2008-10-20 Formulation d'anticorps monoclonal humain anti-igf-1r MA30345B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
MA30345B1 true MA30345B1 (fr) 2009-04-01

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31308A MA30345B1 (fr) 2006-03-28 2008-10-20 Formulation d'anticorps monoclonal humain anti-igf-1r

Country Status (18)

Country Link
EP (1) EP1998806A1 (fr)
JP (1) JP2009531371A (fr)
KR (1) KR20080104160A (fr)
CN (1) CN101410137A (fr)
AR (1) AR060130A1 (fr)
AU (1) AU2007229554A1 (fr)
BR (1) BRPI0709229A2 (fr)
CA (1) CA2647111A1 (fr)
CL (1) CL2007000797A1 (fr)
CR (1) CR10295A (fr)
EC (1) ECSP088778A (fr)
IL (1) IL193904A0 (fr)
MA (1) MA30345B1 (fr)
MX (1) MX2008012295A (fr)
NO (1) NO20083895L (fr)
RU (1) RU2008142359A (fr)
TW (1) TW200815029A (fr)
WO (1) WO2007110339A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CA2681743A1 (fr) * 2007-03-22 2008-09-25 Imclone Llc Formulations d'anticorps stables
JP2010531340A (ja) * 2007-07-10 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー 新規処方物
CN101874040A (zh) * 2007-11-29 2010-10-27 弗·哈夫曼-拉罗切有限公司 免疫球蛋白聚集体
WO2009080541A1 (fr) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Formulation d'anticorps
WO2010069858A1 (fr) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
WO2012135408A1 (fr) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Formulations stables d'anticorps dirigés contre le récepteur humain pd-1 de la mort programmée et traitements associés
CN102363040B (zh) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 用于粘膜组织的抗微生物肽制剂
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA2904806C (fr) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Anticorps modifies se liant au fcrn humain et procedes d'utilisation
CA2904805A1 (fr) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Anticorps asymetriques modifies liant a la recepteur fc et procedes d'utilisation
CN103505729B (zh) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 一种稳定的狂犬病毒人源抗体组合制剂
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
CN110981957B (zh) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
CA2950392A1 (fr) * 2014-05-28 2015-12-03 Nono Inc. Formulation lyophilisee de tat-nr2b9c avec capteur d'acetylation
AR102198A1 (es) * 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EP3357508A4 (fr) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Préparation pharmaceutique d'anticorps anti-pd-1 stable et application de celle-ci dans un médicament
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102759512B1 (ko) 2016-10-25 2025-02-03 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019060062A1 (fr) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. Procédés de réduction de la formation de particules et compositions formées par ceux-ci
TWI919355B (zh) 2018-07-02 2026-03-21 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
CN114324882B (zh) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 蛋白稳定剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
CA2519113C (fr) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体

Also Published As

Publication number Publication date
NO20083895L (no) 2008-10-24
JP2009531371A (ja) 2009-09-03
CA2647111A1 (fr) 2007-10-04
IL193904A0 (en) 2011-08-01
RU2008142359A (ru) 2010-05-10
CN101410137A (zh) 2009-04-15
MX2008012295A (es) 2008-10-09
EP1998806A1 (fr) 2008-12-10
ECSP088778A (es) 2008-10-31
AU2007229554A1 (en) 2007-10-04
BRPI0709229A2 (pt) 2011-06-28
WO2007110339A1 (fr) 2007-10-04
TW200815029A (en) 2008-04-01
CR10295A (es) 2008-10-06
AR060130A1 (es) 2008-05-28
KR20080104160A (ko) 2008-12-01
CL2007000797A1 (es) 2008-01-25

Similar Documents

Publication Publication Date Title
MA31984B1 (fr) Formulation d'anticorps
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA50752A (fr) Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation
FR23C1029I2 (fr) Compositions d'anticorps anti-ctla-4
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
BR0316670A (pt) Anticorpos quiméricos e humanizados para integrina (alfa)5ß1 que modulam a angiogênese
PT1557462E (pt) Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
UA92505C2 (ru) Композиции на основе антитела против cd3
EA200601670A1 (ru) Конъюгаты гидроксиалкилкрахмала и белка
BR0208338A (pt) Derivados de piridina
EP2244729A4 (fr) Anticorps obtenus par la cystéine pour conjugaison spécifique d'un site
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
MA30474B1 (fr) Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee.
MA30042B1 (fr) Composes calcilytiques